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Abstract A large soluble N-terminal fragment of Alzheimer's 
disease amyloid precursor protein (secreted form of APP: APPs) 
is produced by constitutive processing in the middle of the amyloid 
E-protein portion of APP. Recent studies indicate that the activa- 
tion of endogenous protein kinase C (PKC) with phorbol ester 
raises the rate of secretion of APP,. We constructed rat fibroblast 
3Y1 cells that stably overexpress PKC isoenzymes a, ~, or c, and 
analyzed the amount of APPs released from these PKC transfec- 
tants. The levels of APP~ released from 3Y1 cells overexpressing 
PKCa and -e were higher than those from PKC0-transfected and 
control cells expressing vector only. These results suggest that 
specific isoforms of PKC regulate the secretion of APP~ through 
a signaling pathway. 
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novel PKC (nPKC), and atypical PKC (aPKC)) are reported 
in mammalian tissues [20]. It is still unknown which PKC 
group(s) mediates the secretion of APP,. Thus, in order to 
analyze which PKC species is responsible for the secretion of 
APPs, we selected three PKC isoenzymes with different activa- 
tion profiles by phorbol esters (e.g. 12-O-tetradecanoylphorbol 
13-acetate (TPA), phorbol dibutylate (PDBu)) [21], and exam- 
ined the secretion of APPs from rat fibroblast 3YI cells after 
transfection with their full-length cDNA [4]. cPKC members 
show Ca2+-dependency for activity [21], while the activation of 
nPKC and aPKC do not require Ca 2+. We chose cPKCc~ be- 
cause it is widely distributed in most tissues, especially in brain 
[22]. nPKC~ was also selected because of its universal distribu- 
tion among most tissues [23 25]. Finally we introduced brain- 
specific nPKCe cDNA into 3YI fibroblasts. We measured the 
level of APPs in the medium of PKC-transfected 3Y1 cells in 
the presence and absence of TPA. 
I. Introduction 
Alzheimer's disease is characterized by the formation of am- 
yloid plaques containing amyloid fl-protein (Aft) in brain re- 
gions important for intellectual function. The accumulation of 
Aft results in neuronal death and progressive loss of cognitive 
function and memory. Aft, a 39M3-amino acid peptide, is gen- 
erated by proteolytic processing of APP, which has three major 
alternative spliced isoforms, APP695, APP751, and APP770 
[5-10]. In normal brain, APP is degraded within the Aft domain 
by c~-secretase, and a 90-100 kDa soluble non-amyloidogenic 
NH2-terminal fragment of APP (APP,) is secreted from the cells 
[11-15]. Aft is not generated from this process. 
It has been shown that the metabolism of APP is highly 
regulated not only by extracellular signals, such as hormones, 
but also by intracellular second messengers [11,16,17]. Espe- 
cially, the activation of PKC by treatment with phorbol ester 
can increase the secretion of APP~ [1-3] and reduce the produc- 
tion of amyloidogenic fragments containing Aft and Aft itself 
[18,19]. It should be noted that the phosphorylation of APP 
itself is not enhanced by PKC activation. Thus, it is posssible 
that a target protein for phosphorylation by PKC could be an 
APP processing enzyme such as c~-secretase or coated proteins 
in the trafficking vesicle containing APP S. 
Three different groups of  PKC (conventional PKC (cPKC), 
*Corresponding author. Fax: (813 (3) 3813-0654. 
2. Experimental 
2.1. Cell culture 
Rat fibroblast 3Y1 cells were transfected with full-length cPKC~, 
nPKC~, or nPKCe cDNAs with a neomycin resistance gene [4]. These 
cells were maintained inDulbecco's modified Eagle's medium (DMEM; 
Nissui) containing 10% (v/v) fetal bovine serum and 200 mg/ml G418 
(Gibco) in an atmosphere of 5% CO495% air at 37°C. 
2.2. Antibodies 
In order to analyze and detect he processing products of APP from 
3YI cells, we raised several kinds of antibodies against a portion of 
APE Antibodies GID andfll 16 were produced against synthetic pep- 
tides corresponding to amino acid residues 175 186 and 597 612 of 
APP695, respectively [26]. Anti-PN antibody was raised against puri- 
fied APP s from APP695 cDNA transfected COS-I cells. We also used 
monoclonal anti-APP NH~-terminal antibody 22Cll (Boehringer 
Mannheim) [12]. 
2.3. Measurement o/' APP~ release 
PKC-overexpressing 3Y1 cell lines grown to subconfluence were 
incubated in serum-free DMEM with 100 nM TPA or 0.1% DMSO for 
24 h. To analyse APP~ from control and PKC-overexpressing cell lines, 
culture media were collected and centrifuged at 10,000 x g to remove 
cells and debris. The media (7.5 ml) were desalted and concentrated on 
a PD-10 column (modified from [16]). The column eluates were frozen 
in liquid N 2 and dried under vacuum, and then dissolved in SDS-sample 
buffer. The samples were boiled for 5 rain, separated by SDS-PAGE 
[27], and electroblotted onto polyvinylidene difluoride membranes (Im- 
mobilon-P, Millipore). The volumes of the loaded samples were nor- 
malized for the total number of the cells. Western blots were probed 
with monoclonal antibody 22C1 I, rabbit antisera PN, or GID. Each 
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antibody and antisera was used at 1 : 1000 dilution. Binding of antibod- 
ies was detected by chemiluminescence (ECL, Amersham). The bands 
were quantified using an Imagemaster (Pharmacia). 
2.4. PDBu-binding assay 
PKC cDNA transfected 3Y1 cells were grown to subconfluence in
60-mm dishes, the culture medium was removed, and the cells were 
washed in a total volume of 6 ml of binding solution (DMEM, 1 mg/ml 
of bovine serum albumin, 10 mM HEPES (N-2-hydroxyeth- 
ylpiperazine-N'-2-ethanesulfonic acid), pH 7.0). The 3Y1 ceils were 
then treated with 2 ml of binding solution for 20 min in a CO2 incubator. 
The binding solution was removed, and 1 ml of a solution including 
30/.tM tritium-labelled PDBu ([3H]PDBu) was added to the dish and 
the cells were incubated for 30 min at 37°C until the [3H]PDBu had 
bound to PKCs in the cells [28]. Three ml of cold phosphate buffered 
saline was added to the dish on ice to stop the reaction. The cells were 
washed twice, collected, and the radioactivity was measured by a liquid 
scintillation counter. 
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Fig. 1. APPs is released into the medium when rat fibroblast 3Y1 cells are treated with TPA. (A) Desalted and freeze-dried media were analyzed after 
electrophoresis by Western blotting with antibodies against the N-terminal of APP, PN. Control and PKC-overexpressing 3Y1 ceils were treated with 
100 nM TPA (represented by +) or 0.1% DMSO (represented by -).  1 or 2 indicates PKC-transfected clone picked up independently. ~,~ and E, 
express the sample from PKCa, -~ and -e-transfected cells. The volume of sample loaded in each lane was corrected for the number of cells per dish. 
The large arrow indicates APP,. A major species of APP~ is a KPI containing type [37]. Size markers are shown on the right. (B) Levels of APP~ 
released into he medium. Control and PKC-overexpressing 3Y1 cells were incubated for 24 h in DMEM containing 100 nM TPA. Data are expressed 
as absorbance l vel (ABS) of APP~ from cells. 
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Fig. 2. Quantification of PKC expression i  each transfectant by 
[3H]PDBu-binding assay. Data are expressed asthe percent of radioac- 
tivity of [3H]PDBu that bound to control cells. The symbols refer to 
PKC-transfected clones; for example, c~-1 means one PKCct-transfected 
cell. 
3. Results and discussion 
To examine which PKC isotypes mediate the secretion of 
APPs, we constructed rat fibroblast 3Y1 cells that stably over- 
expressed three kinds of PKCs: cPKC~, nPKC5 and nPKCe 
[4]. We chose two PKC-transfected clones independently and 
measured the APPs levels released into the medium treated with 
TPA or dimethylsulfoxide (DMSO) by Western blot analysis 
(Fig. 1A). Although the primary antibody used for Western 
blotting was anti-PN originally derived from human APPs, anti- 
human APP antibodies could recognize rat APPs as shown in 
Fig. 1A. When these cell lines were treated with TPA, the 
secretion of APP~ drastically increased. Quantification of se- 
creted APPs levels by densitometry showed that cPKC~ and 
nPKCe-overexpressing celllines experienced 8-fold and 6-fold 
higher increases in secreted APPs levels, respectively, than con- 
trol cells (Fig. I B). When we treated nPKCS-overexpressing 
cell lines with TPA or DMSO, the quantity of APP s secreted 
was almost equal to the levels in control cells transfected with 
expression vector only. Although treatment with DMSO (i.e. 
-TPA) did not affect APPs secretion in any transfectants, he 
addition of TPA raised the rate of secretion in cPKC~- and 
nPKCe-transfected cells. These results indicate that cPKCct 
and nPKCe, but not -6, increase APP~ secretion in response to 
TPA. 
However, it was not clear how much PKC was expressed in 
transfected 3YI cells. Therefore, the above results do not nec- 
essarily reflect the increase in activity of PKC for APP s secre- 
tion. To analyze the expressed PKC level in transfected cells 
quantitatively, we performed PDBu-binding assays (Fig. 2) [28]. 
This assay is based on the fact that PKC binds PDBu stoi- 
chiometrically, and allows the simple estimatation of the rate 
of APPs secretion per PKC molecule. Table 1 shows the specific 
activities of one PKC molecule for APP~ secretion, nPKCe had 
the highest specific activity for APP~ secretion among the three 
kinds of PKCs. The results strongly suggest hat nPKCe, as 
well as cPKCct, is involved in APP s secretion in the brain. 
PKC takes part in cell signaling and occurs in many cellular 
responses. The cPKC~ and nPKC~ used in this study are dis- 
tributed in almost all tissues, while nPKCe is expressed mainly 
in the brain and secretory cells [20]. Since APP is expressed in 
almost every tissues [29] and APP s is a kind of secretory mole- 
cule, the localized istribution of nPKCe in the brain strongly 
suggests its involvement in neuronal function. 
In this paper, we report hat cPKC~ and nPKCe specifically 
increase the quantity of APPs degraded by ct-secretase, while 
nPKC~ does not change the level of APPs. These results may 
indicate a difference in the intracellular localization of PKC 
isoforms. The reason we did not transfect an aPKC species into 
cells is that little is known about he cellular egulatory systems 
of aPKCs compared with those of cPKCs and nPKCs. In addi- 
tion, aPKCs contain only one cysteine-rich zinc finger-like do- 
main, making them independent of diacylglycerol and phorbol 
esters (exogenous PKC activator) [30,31]; thus we cannot con- 
trol the activity of aPKCs in transfected cells with phorbol 
esters uch as PDBu. 
The next question involves the target(s) of PKC in APP S 
secretion. First, it is expected that PKC directly phosphorylates 
the APP molecule in vivo. It has been reported that PKC 
directly phosphorylates APP in vitro and in semi-intact ells 
[32,33]; however, a recent report suggests that the phosphoryl- 
ation of the C-terminal domain of APP is independent of the 
release of APP s by phorbol ester treatment [34]. Almost all 
potential phosphorylation sites in APP by protein kinases uch 
as PKC and casein kinase II exist on the N-terminal, and 
phosphorylation in the ecto-domain of APP may induce con- 
formational change resulting in degradation by intracellular 
proteases. A second possibility is that PKC may control the 
activity of ct-secretase by phosphorylation. However, the iden- 
tity of the putative ~-secretease remains to be determined. 
Our data demonstrate hat some isotypes of brain-specific 
PKC promote an increase in the release of APP,, and the other 
isotypes are not involved in this process. We are interested in 
the involvement of nPKCe in the release of APE because 
nPKCe, but not PKCd;, is activated by cis-unsaturated fatty 
acids [24,35]. When a cell expressing cPKC~ and nPKCe tries 
to secrete APP S more effectively, the phosphotipases that pro- 
duce the cis-forms of fatty acids must first be activated, and 
then activation of PKC subtype(s) may follow the increase in 
Table 1 
The difference inthe ability of PKC species to enhance APP secretion 
APP s : ABS/cell PKC : [3H]PDBu/cell APPJPKC 
Control 100 100 1 
c~-I 695 261 2.66 
c~-2 777 253 3.07 
~-1 0 82 0 
~;-2 52 21 2.47 
e-I 436 80 5.45 
e-2 507 117 4.33 
Data for both APP~:ABS/cell and PKC:[3H]PDBu/cell are expressed 
as the percents of control (n = 3). The values of both APP~:ABS/cell 
and PKC: [3H]PDBu/cell are shown in Fig. 1B and Fig. 2, respectively. 
Therefore, in the APPs/PKC lane, the specific activity of one cDNA- 
derived PKC molecule to secrete APP s is estimated as 1 of the value of 
control. As a result, it was strongly suggested that nPKCe as well as 
cPKCc~ aggressively act as mediators to secrete APP,. 
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the intracellular concentration f unsaturated fatty acids. Alter- 
natively, nPKCe is directly activated by an unidentified signal, 
such as lipid derivatives like prostaglandins. Reports from 
other laboratories have suggested that transfection of cPKCc~ 
cDNA into Swiss 3T3 fibroblasts enhances APPs secretion 
upon TPA treatment, indicating that at least cPKC~ is neces- 
sary for TPA-induced APP~ release [36]. Our results suggest 
that not only cPKC~ but also nPKCe is required for APP 
secretion, although the mechanism of enhancement is remains 
unknown. Interestingly, the introduction of nPKCe into 3Y1 
cells also increased APP~ release without an external signal such 
as TPA. Therefore, nPKCe might be involved in basal APP~ 
release in neural cells. 
Further work is necessary to elucidate the role of PKC sub- 
types in the secretion of APPs molecules. 
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